Health Care • Biotechnology: Pharmaceutical Preparations
$86.39 ▲ +0.58
(+0.68%)
MKT CAP: $5.61B • VOL: 591.4K
52W L $63 52W H $130
MIRM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $521.3M | $336.9M | $186.4M |
| YoY Revenue Growth % | +54.7% | +80.8% | — |
| Gross Profit | $229.4M | $148.2M | $82.0M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.1M | -$87.6M | -$109.2M |
| Operating Margin % | -4.2% | -26.0% | -58.6% |
| Net Income (GAAP) | -$23.4M | -$87.9M | -$163.4M |
| EBITDA (Normalized) | -$21.4M | -$86.8M | -$102.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $55.8M | $10.3M | -$70.9M |
| Capital Expenditures (CapEx) | $954.0K | $993.0K | $8.4M |
| Free Cash Flow (FCF) | $54.9M | $9.3M | -$79.3M |
| FCF Margin % | 10.5% | 2.8% | -42.6% |
| Return on Invested Capital (ROIC %) | -6.8% | -34.0% | -4.6% |
| Cash & Short-Term Equivalents | $296.7M | $222.5M | $339.4M |
| Total Debt (Short + Long Term) | $237.7M | $200.3M | $721.9M |
| Total Stockholders' Equity | $314.7M | $225.6M | $1.48B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MIRM.